Invention Grant
US09402846B2 Combination of inhibitor of B-Raf and inhibitor of AKT in the treatment of cancer
有权
B-Raf抑制剂与AKT抑制剂联合用于治疗癌症
- Patent Title: Combination of inhibitor of B-Raf and inhibitor of AKT in the treatment of cancer
- Patent Title (中): B-Raf抑制剂与AKT抑制剂联合用于治疗癌症
-
Application No.: US14456180Application Date: 2014-08-11
-
Publication No.: US09402846B2Publication Date: 2016-08-02
- Inventor: Melissa Dumble , Tona Gilmer , Rakesh Kumar , Sylvie Laquerre , Peter F. Lebowitz , Shannon Renae Morris
- Applicant: Novartis AG
- Applicant Address: CH Basel
- Assignee: Novartis AG
- Current Assignee: Novartis AG
- Current Assignee Address: CH Basel
- Agent Michelle Han
- Main IPC: A61K31/506
- IPC: A61K31/506 ; A61P35/00 ; A61P35/02 ; A61K31/4155 ; A61K45/06

Abstract:
The present invention relates to a method of treating cancer in a human and to pharmaceutical combinations useful in such treatment. In particular, the method relates to a cancer treatment method that includes administering N-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide or a pharmaceutically acceptable salt thereof, and N-{(1S)-2-amino-1-[(3,4-difluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-furancarboxamide, or a pharmaceutically acceptable salt thereof, to a human in need thereof.
Public/Granted literature
- US20140350039A1 COMBINATION Public/Granted day:2014-11-27
Information query
IPC分类: